AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Home hLife Article
Article Link
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Letter | Open Access

BCMA-CD19 bispecific CAR-T therapy in refractory chronic inflammatory demyelinating polyneuropathy

Wei Zhang1,#Dan Liu2,3,4,#Tao Zhang1Jiang Cao5Gang Wang2,3,4Huizhong Li2,3,4Su Zhou1Ruixue Zhang1Yuqiao Wang1Jinyu Li1Zixuan Zhang1Hao Chen1Yong Zhang1Shenyang Zhang1Jie Zu1Xiaopeng Wang1Chuanying Xu1Manli Zhou1Ming Shi2,3,4( )Guiyun Cui1( )Junnian Zheng4 ( )
Department of Neurology, The Affiliated Hospital of Xuzhou Medical University, Jiangsu, China
Cancer Institute, Xuzhou Medical University, Jiangsu, China
Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, Jiangsu, China
Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Jiangsu, China
Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Jiangsu, China

#These authors contributed equally to this work

Show Author Information

References

【1】
【1】
 
 
hLife
Pages 434-438

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Zhang W, Liu D, Zhang T, et al. BCMA-CD19 bispecific CAR-T therapy in refractory chronic inflammatory demyelinating polyneuropathy. hLife, 2024, 2(8): 434-438. https://doi.org/10.1016/j.hlife.2024.05.005

1122

Views

17

Crossref

Received: 12 March 2024
Revised: 22 May 2024
Accepted: 23 May 2024
Published: 28 May 2024
© 2024 The Authors.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).